The global awakening: How ADHD became the defining health system challenge of a generation
An explosion in ADHD interest Over the last 20 [...]
Deals, Data, and the NHS: Healthcare Investment in 2026
Last week CF’s Health Investing leadership team [...]
Reflections from IPPR’s new report launch – Bismarck versus Beveridge Revisited
Capital concerns I was in the room [...]
ADHD Review: Interim findings lay bare the complexity of the ‘overdiagnosis’ debate
Amid growing debate around ADHD ‘overdiagnosis’, the UK [...]
NICE 2026: The goalposts have moved
Three to six months. That is the time saving [...]
Transforming women’s healthcare: Lessons from Ireland
On International Women’s Day 2022 we launched Ireland’s first [...]
We have turned a corner: What the ARUK conference told us about the future of dementia treatment
The CF Life Sciences team attended the ARUK 2026 [...]
SEND Reform: Putting Children and Young People First
As part of the Department for Education's [...]
Inside the NHS’s National Cancer Plan for England 2026-2035
Cancer remains England's biggest killer, affecting 1 [...]
Reflecting on JP Morgan Healthcare Conference 2026: What the strategic shifts mean for delivering innovation to patients
As the dust settles from the JP Morgan Healthcare [...]
